BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT

NCT05846737 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped The study was withdrawn due to the inability to enroll participants.

Conditions

Multiple Myeloma

Interventions

BIOLOGICAL: anti-BCMA CAR-T

Sponsor

Institute of Hematology & Blood Diseases Hospital, China